A5071282780- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS Research and Interventions
- Viral-associated cancers and disorders
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- HIV Research and Treatment
- Cervical Cancer and HPV Research
- SARS-CoV-2 detection and testing
- Lymphoma Diagnosis and Treatment
- HIV, Drug Use, Sexual Risk
- Polyomavirus and related diseases
- Syphilis Diagnosis and Treatment
- COVID-19 and Mental Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- HIV, TB, and STIs Epidemiology
- Aortic aneurysm repair treatments
- Inflammasome and immune disorders
- Respiratory Support and Mechanisms
- Myasthenia Gravis and Thymoma
- Pericarditis and Cardiac Tamponade
- Gut microbiota and health
- HIV/AIDS oral health manifestations
- RNA Interference and Gene Delivery
Universitat de Miguel Hernández d'Elx
2018-2025
Hospital General Universitario de Elche
2018-2025
Instituto de Salud Carlos III
2021-2025
Centro de Investigación en Red en Enfermedades Cardiovasculares
2025
Association Clinique et Thérapeutique Infantile du Val de Marne
2024
Centro de Investigación Biomédica en Red
2023-2024
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
2021
BackgroundThe virological and immunological effects of the immunomodulatory drugs used for COVID-19 remain unknown. We evaluated impact interleukin (IL)-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics antibody response in patients COVID-19.MethodsProspective cohort study admitted COVID-19. Serial nasopharyngeal plasma samples were measured RNA S-IgG/N-IgG titers, respectively.Findings138 confirmed infection included; 76 (55%) underwent IL-6 blockade. Median initial SOFA (p = 0•016)...
The interdependencies of viral replication and the host immune response in patients with coronavirus disease 2019 (COVID-19) remain to be defined. We investigated determinants antibody response, predictors nonseroconversion, role antibodies on dynamics.This was a prospective study hospitalized COVID-19 that microbiologically confirmed by real-time polymerase chain reaction (RT-PCR). Serial nasopharyngeal oropharyngeal swabs plasma samples were obtained for measuring severe acute respiratory...
Background The pathophysiology of long-COVID remains unknown, and information is particularly limited for symptoms very long duration. We aimed to assess the serological, T-cell immune responses ANA titers patients with long-COVID-19 syndrome 1-year Methods Prospective, longitudinal study hospitalized COVID-19 followed-up 12 months. Sequential blood samples symptom questionnaires (CSQ) were obtained, humoral cellular responses, antinuclear antibodies (ANA) inflammation biomarkers analyzed....
BackgroundWhether interleukin-6 (IL-6) blockade in patients with COVID-19 will affect the protective immunity against SARS-CoV-2 has become an important concern for anti-IL-6 therapy. We aimed to investigate effects of IL-6 on long-term SARS-CoV-2.MethodsProspective, longitudinal cohort study conducted hospitalized severe or critical laboratory confirmed infection. assessed humoral (anti-S1 domain spike [S], anti-nucleocapsid [N], anti-trimeric [TrimericS] IgG, and neutralizing antibodies...
This prospective study aimed to determine the prevalence of long COVID in patients hospitalized for SARS-CoV-2 infection from March 2020 July 2022 and assess impact different viral lineages. A total 2,524 were followed up 12 months, with persistent symptoms reported 35.2% at one month, decreasing thereafter. Omicron variant initially showed higher symptom intensity, but this trend diminished over time. Certain lineages, notably Delta lineages AY.126 AY.43, sublineages BA.1.17, BA.2.56,...
Abstract Background This study aimed to investigate factors contributing non-sustained viral suppression, including intermittent viremia and persistent low-level viremia, during cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) injectable therapy, with a focus on pharmacokinetics (PK). Methods A prospective cohort was conducted people HIV (PWH) transitioning from stable oral antiretroviral therapy (ART) bimonthly CAB+RPV LA. Standardized follow-up included close monitoring through...
Abstract Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial severely ill patients, but no data are available on earlier stages disease. An anticipated blockade might hypothetically prevent catastrophic consequences overt storm. We evaluated early-given tocilizumab patients...
We evaluated a standardized interferon-γ (IFN-γ) release assay (IGRA) for detection of T-cell immune response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination.This prospective study included patients with disease 2019 (COVID-19) different severity illness and follow-up (FU), vaccinated subjects, healthy unvaccinated persons. SARS-CoV-2 was measured using specific quantitative IGRA in whole blood (Euroimmun, Germany) TrimericS-IgG neutralizing...
The impact of long-acting injectable cabotegravir plus rilpivirine (CAB/RPV) on rectal HIV-1 RNA dynamics and the factors associated with viral shedding remain poorly understood. This prospective study evaluated by analyzing sequential paired plasma fluid samples from virologically-suppressed individuals who transitioned oral antiretroviral therapy (ART) to every-two-month CAB/RPV (preceded or not lead-in), over a 9-month follow-up period. RPV trough concentrations were measured in 384...
We aimed to determine the predictive accuracy of elevated soluble thrombomodulin (sTM) and angiopoietin-2 (Ang2) for thrombotic events (TE) in hospitalized COVID-19 patients. conducted a nested case-control study within cohort people admitted hospital with from March 2020 August 2022. The cases (people TE 28 days after admission) were matched by propensity score comparable patients without TE. determined plasma levels sTM Ang2 all available frozen samples, prioritizing earliest...
To assess the benefits of remdesivir in hospitalized COVID-19 patients receiving combined immunomodulatory therapy (CIT) with dexamethasone and tocilizumab.This was a cohort study microbiologically confirmed patients. The primary outcome all-cause 28 day mortality. Secondary outcomes were need for invasive mechanical ventilation (IMV) IMV/death. Subgroup analyses according to SARS-CoV-2 cycle threshold (Ct) values inflammation biomarkers performed. Multivariable marginal structural Cox...
Integrase strand transfer inhibitors (INSTI) have been associated with weight gain, but their effect on short-term overweight and obesity incidence, blood pressure (BP), metabolic markers has not described in treatment-naïve people HIV(PWH).Medical records of persons starting antiretroviral therapy (ART) at the HIV Clinic University Hospital Elche, Spain, between January 2007 July 2019 were reviewed retrospectively. Standard procedures included measurements weight, BP, assessment. Data...
Background Chagas disease (CD) is a chronic parasitic caused by Trypanosoma cruzi and endemic to continental Latin America. In Spain, the main transmission route congenital. We aimed assess adherence regional recommendations of universal screening for CD during pregnancy in American women province Alicante from 2014 2018. Methodology/Principal findings Retrospective quality study using two data sources: 1) delivery records that gave birth 10 public hospitals between January December 2018; 2)...
Background: Baricitinib is a Janus kinase (JAK) inhibitor with broader anti-inflammatory activity than tocilizumab and an antiviral potential although no head-to-head trials are available. The benefits of adding baricitinib to patients COVID-19 experiencing clinical progression despite the standard care (SOC), including corticosteroids tocilizumab, also unknown. Methods: A cohort study included microbiologically confirmed hospitalizations. primary outcome was 28-day mortality. Secondary...
ABSTRACT Objective Long-term data following SARS-CoV-2 infection are limited. We aimed to characterize the medium and long-term clinical, virological, immunological outcomes after hospitalization for COVID-19, identify predictors of long-COVID. Methods Prospective, longitudinal study conducted in COVID-19 patients confirmed by RT-PCR. Serial blood nasopharyngeal samples (NPS) were obtained measuring RNA S-IgG/N-IgG antibodies during hospital stay, at 1, 2 6 months post-discharge. Genome...
To analyze the incidence rates (IR) and spectrum of vascular events in people living with HIV (PLWH) Spain from 2004 to 2015. Serial measurements different plasma cardiovascular biomarkers were assessed relation disease development.
Abstract Background The relationship of microbiota composition dynamics and the progression subclinical atherosclerosis in people with human immunodeficiency virus (PWH) remains unknown. Methods A 96-week, prospective, longitudinal study was performed virologically suppressed PWH. Carotid intima-media thickness (cIMT) measurements stool samples were obtained at baseline 48- 96-week visits. cIMT defined as an increase >10% and/or detection new carotid plaque. To profile gut microbiome,...
Non-AIDS defining malignancies present a growing challenge for persons with HIV (PWH), yet tailored interventions timely cancer diagnosis are lacking. The Spanish IMPAC-Neo protocol was designed to compare two comprehensive screening strategies integrated into routine care. This study reports baseline data on the prevalence and types of precancerous lesions early-stage among participants at enrolment. Acceptability procedure additionally assessed.
The incidence of non-AIDS defining cancer (NADC) is higher in people living with HIV (PLWH) than the general population, and it already one leading causes death HIV-infected population. It estimated that situation will be aggravated by progressive aging PLWH. Early diagnosis through intensive screening may improve ability for therapeutic interventions could critical reducing mortality, but might also increase expenditure harms associated adverse events. aim this study to evaluate an enhanced...
Abstract Background We aimed to assess the relationship between sexually transmitted infections (STIs)—including a large panel of human papillomavirus (HPV) genotypes—and high-grade anal intraepithelial neoplasia (HGAIN) in men who have sex with (MSM) were living immunodeficiency virus (HIV). Methods In prospective study an HIV cohort, participants underwent high-resolution anoscopy (HRA) for anorectal swabs collection investigate STIs and biopsy. Multiplex real-time polymerase chain...
Abstract Background The time at which the protective effect of starting ART is achieved in male rectal and genital reservoirs not clearly established. Objectives To quantify HIV-1 RNA decay towards virological suppression mucosa semen MSM dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). Methods A longitudinal cohort study ART-naive HIV-positive was performed. quantified seminal plasma samples day 1 initiation (baseline) every 4 weeks until week 20 (w20; all participants) 64 (w64; 6 12...